secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0000950170-25-087678
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health gets two new U.S. patents for duodenal resurfacing, portfolio now 31 granted patents
--------------------------------------------------------------------------------

- U.S. Patent No. 12,329,439 (June 17, 2025) and No. 12,303,185 (May 20, 2025) cover thermal and non-thermal electrical energy ablation of duodenal mucosa.
- Total IP estate: 31 granted U.S. patents and ~40 pending applications, built since 2011.
- Revita next milestones: REVEAL-1 open-label data June 2025, REMAIN-1 midpoint Q3 2025, primary endpoint H2 2026.
- Patents reinforce Fractyl's leadership in gut-targeted metabolic therapies for obesity and type 2 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/0000950170-25-087678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017025087678/guts-20250618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-087678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer